Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24798325 | 0.84 | ACACB (0.38) | ALOX15ACACBCRHR1HCRTR1HCRTR2 | |
| SCHEMBL13806015 | 0.81 | TAAR1 (0.39) | ALOX15ACACBCRHR1KMT2ANPSR1 | |
| SCHEMBL13806027 | 0.80 | HRH3 (0.51) | HCRTR1HCRTR2HRH3MTNR1AMTNR1B | |
| SCHEMBL1586782 | 0.78 | DYRK1A (0.42) | — | |
| SCHEMBL4259756 | 0.78 | TAAR1 (0.40) | ACACBKMT2AHRH3MTNR1AMTNR1B | |
| SCHEMBL10144707 | 0.78 | HRH3 (0.41) | ACACBKMT2AHRH3MTNR1AMTNR1B | |
| SCHEMBL12870911 | 0.76 | CRHR1 (0.46) | CRHR1HCRTR1HCRTR2 | |
| SCHEMBL13384561 | 0.75 | ACACB (0.39) | ACACBHCRTR1HCRTR2HRH3MTNR1A | |
| SCHEMBL13806050 | 0.75 | CRHR1 (0.39) | ALOX15CRHR1KMT2AHCRTR1HCRTR2 | |
| SCHEMBL13403110 | 0.73 | CRHR1 (0.40) | ALOX15CRHR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940771-B2 | Organic compounds | NOVARTIS AG (CH) | 2015-01-27 | — | — | US | disclosed |
| US-8940771-B2 | Organic compounds | NOVARTIS AG (CH) | 2015-01-27 | — | — | US | disclosed |
| US-7696210-B2 | Gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090163469-A1 | Organic Compounds | NOVARTIS AG | 2009-06-25 | — | — | US | disclosed |
| US-20090163469-A1 | Organic Compounds | NOVARTIS AG | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163469-A1 | Organic Compounds | PIK3C3, PIK3CA, PIK3CD | ALOX15 2664/4885ACACB 1200/4885CRHR1 4774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.